Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)

NCT05029531 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia, Pediatric
ALL, Infants

Interventions

COMBINATION_PRODUCT: the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology